Tag:
AstraZeneca
Latest Headlines
Latest Headlines
AstraZeneca revs up PhIII cancer plans as rivals steal ASCO spotlight
Determined to prove to investors that AstraZeneca has a late-stage game plan that can rescue the pharma company from a lengthy losing streak, the company today spotlighted plans to speed up the Phase III development timeline on three key cancer drugs.
AstraZeneca, Astellas among Optimer bidders, Bloomberg sources say
Who wants Optimer Pharmaceuticals and its high-powered antibiotics? A handful of drugmakers, apparently.
UPDATED: Biotech trio to take over Alderley labs as AstraZeneca heads south
It's the start of what locals hope will be a continued migration of smaller companies to the Alderley campus to fill the void of AZ's massive exit from the area.
Ex-Genzyme chief Termeer joins board at Cambridge biotech
Moderna, which struck a major development deal with AstraZeneca just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors
AstraZeneca pitches in to develop NHS social-media app
The U.K.'s struggling AstraZeneca is not only looking to media that is social to develop some kind of relationship with patients; it has gone local as well.
U.K. union makes its case against AstraZeneca's R&D relocation
A Unite official called the move--expected by 2016 after AstraZeneca builds a major new headquarters and R&D facility in the science hub--both a massive blow to the regional economy as well as a possible spoiler for research productivity at a time the company is facing some stiff headwinds.
AstraZeneca helps NHS develop social media app for U.K. market
The U.K.'s struggling AstraZeneca is not only looking to media that is social to develop some kind of relationship with patients; it has gone local as well.
Vapotherm finalizes $29M financing round for vapor device expansion
Vapotherm, a maker of respiratory therapy devices, sealed the final deal on a $29 million round of funding to help propel growth plans, the company disclosed this week. And a whopping seven investors are involved.
Analysts skeptical as AstraZeneca sales, earnings sink
AstraZeneca's first-quarter sales dropped by 12%. Core earnings fell by 21%. Neither number approached Bristol-Myers Squibb's scary declines. Both companies are suffering big-time hits to their top drugs, because of generic competition. AstraZeneca's earnings actually beat expectations. So why are AstraZeneca analysts less positive about the company's results? It's all about the future.
U.S. feds launch probe into AstraZeneca plant in U.K.
U.S. federal investigators have taken an interest in manufacturing at an AstraZeneca plant in England, but the company is remaining mum about what precisely they want to know.
